- Mirati Therapeutics (MRTX +9.3%) is up on below-average volume in apparent response to Amgen's R&D update during its Q2 earnings call after the close yesterday. Preliminary data from a Phase 1/2 clinical trial evaluating AMG 510, a KRAS G12C inhibitor, in patients with solid tumors showed tumor responses in colorectal and appendiceal patients (Slide #29 in presentation). In June, Amgen announced data from the study that included responses in lung cancer patients.
- Mirati is also developing a KRAS G12C inhibitor, MRTX849, also in Phase 1/2 development.